Teneobio
Founders
Roland Buelow, Ph.D. - CEO
Ben Buelow, M.D., Ph.D. - Chief Medical Officer
Wim van Schooten, Ph.D. - Chief Scientific Officer
Omid Vafa, Ph.D., MBA - Chief Business Officer
Founded
2009
Stage
Series A
Invested
2016
Status
Acquired by Amgen / Abbvie / AstraZeneca
Lightspeed Team
Christopher Schaepe - Partner
Jonathan MacQuitty - Partner

TeneoBio, Inc. is developing a new class of biologics, Human Heavy Chain Antibodies (UniAbs™), as therapeutics against cancer, autoimmunity, and infectious diseases.

Company was acquired in 2021 by Amgen for $900 million of upfront cash with additional contingent milestone-based cash payments of up to $1.6 billion

Jonathan MacQuitty
Fraction Fraction

Faction Ventures, LLC (“Faction”) and Lightspeed Management Company, L.L.C. (“Lightspeed”) are separate businesses that operate independently of each other. Faction is a registered investment adviser under the United States Investment Advisers Act of 1940, as amended. Faction advises its own fund(s) and does not advise any Lightspeed clients, and Lightspeed does not advise Faction or any of its clients. Lightspeed and Faction are parties to an agreement pursuant to which Lightspeed holds certain interests in Faction and the fund(s) Faction manages.

continue to the Faction Site